# US 2025/0152604 A1 · Contraceptive methods with scheduled bleeding effects

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152604 A1
- Document ID: US20250152604A1
- Status: Published application
- Kind: A1
- Application number: 18/837,118
- Filed: 2023-02-09
- Published: 2025-05-15
- Earliest claimed: 2022-02-10
- Assignees: Estetra Srl
- Applicants: Estetra Srl
- Inventors: Jean-Michel FOIDART; Maud JOST
- Web page: https://patentgrep.com/patent/US20250152604A1

## CPC

- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/567: substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A61K 31/585: containing lactone rings, e.g. oxandrolone, bufalin
- A61P 15/18: Feminine contraceptives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described are methods of providing contraception with increased likelihood of scheduled bleeding in a woman having a BMI<30.0 kg/m2 and methods of providing contraception with reduced likelihood of scheduled bleeding in a woman having a BMI≥30.0 kg/m2. The methods comprise orally administering a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg. Also provided are compositions comprising an estetrol component and drospirenone for use in such methods.

## Claims

### Claim 1

(canceled)

### Claim 2

A method of providing contraception with reduced likelihood of scheduled bleeding in a woman having a BMI≥30.0 kg/m2, comprising:
selecting a woman determined to have a BMI≥30.0 kg/m2, and then
orally administering to the selected woman a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg,
wherein the method comprises administration according to consecutive 28-day cycles of daily administration of the estetrol component and drospirenone on consecutive days 1-24 followed by a hormone-free period without administration of the estetrol component and drospirenone on consecutive days 25-28,
wherein the treated woman has a reduced likelihood of scheduled bleeding on day 25 to day 3 of consecutive 28-day cycles.

### Claim 3 (depends on 2)

The method of claim 2, wherein the estetrol component is estetrol monohydrate.

### Claim 4 (depends on 2)

The method of claim 2, wherein the estetrol component is estetrol monohydrate and is administered at a daily dose of 15 mg and the drospirenone is administered at a daily dose of 3 mg.

### Claim 5 (depends on 2)

The method of claim 2, wherein the method further comprises, prior to the selecting, calculating the BMI of the woman from a measured height and weight of the woman.

### Claim 6 (depends on 2)

The method of claim 2, wherein the selecting comprises selecting a woman determined to have a BMI≥30.0 kg/m2 and ≤35.0 kg/m2.

### Claim 7 (depends on 2)

The method of claim 2, wherein the selecting comprises selecting a woman determined to have a BMI≥30.0 kg/m2 and determined to be 16-50 years old.

### Claim 8 (depends on 2)

The method of claim 2, wherein the selecting comprises selecting a woman determined to have a BMI≥30.0 kg/m2 and determined to be 16-25 years old.

### Claim 9 (depends on 2)

The method of claim 2, wherein the treated woman has a reduced likelihood of experiencing scheduled bleeding on day 25 to day 3 of a 28-day cycle than a woman having a BMI<30.0 kg/m2.

### Claim 10

(canceled)

### Claim 11

A method of providing contraception with an increased likelihood of scheduled bleeding in a woman having a BMI<30.0 kg/m2, comprising:
selecting a woman determined to have a BMI<30.0 kg/m2, and then
orally administering to the selected woman a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg,
wherein the method comprises administration according to consecutive 28-day cycles of daily administration of the estetrol component and drospirenone on consecutive days 1-24 followed by a hormone-free period without administration of the estetrol component and drospirenone on consecutive days 25-28,
wherein the woman has an increased likelihood of scheduled bleeding on any of day 25 to day 3 of consecutive 28-day cycles.

### Claim 12 (depends on 11)

The method of claim 11, wherein the estetrol component is estetrol monohydrate.

### Claim 13 (depends on 11)

The method of claim 11, wherein the estetrol component is estetrol monohydrate and is administered at a daily dose of 15 mg and the drospirenone is administered at a daily dose of 3 mg.

### Claim 14 (depends on 11)

The method of claim 11, wherein the method further comprises, prior to the selecting, calculating the BMI of the woman from a measured height and weight of the woman.

### Claim 15 (depends on 11)

The method of claim 11, wherein the selecting comprises selecting a woman determined to have a BMI<30.0 kg/m2 and determined to be 16-50 years old.

### Claim 16 (depends on 11)

The method of claim 11, wherein the selecting comprises selecting a woman determined to have a BMI<30.0 kg/m2 and determined to be 16-25 years old.

### Claim 17 (depends on 11)

The method of claim 11, wherein the treated woman has an increased likelihood of experiencing scheduled bleeding on day 25 to day 3 of a 28-day cycle than a woman having a BMI≥30.0 kg/m2.
